Tom Jaspers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tom Jaspers has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ann Van Eeckhaut
Research group Experimental Pharmacology (EFAR), Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium
1 shared publication - Dimitri De Bundel
Laboratory of Pharmaceutical Chemistry, Drug Analysis and Drug Information, Research Group Experimental Pharmacology (EFAR), Center for Neurosciences (C4N), Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium
1 shared publication - Elisabeth Rossaert
KU Leuven - University of Leuven, Department of Neurosciences, Experimental Neurology and Leuven Brain Institute (LBI)
1 shared publication - Eveliina Pollari
R&D, Orion Pharma Corporation, Turku, Finland
1 shared publication - Ilse Smolders
Research Group Experimental Pharmacology (EFAR), Center for Neurosciences (C4N), Faculteit Geneeskunde en Farmacie, Vrije Universiteit Brussel (VUB), Brussels, Belgium
1 shared publication - Katrien De Bock
Department of Health Sciences and Technology, Laboratory of Exercise and Health, ETH Zürich, Zurich, Switzerland
1 shared publication
Latest Publications
- 1 September 2021
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1178, 338803
Applicability of cerebral open flow microperfusion and microdialysis to quantify a brain-penetrating nanobody in mice
- 1 September 2021
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1178, 338803
Applicability of cerebral open flow microperfusion and microdialysis to quantify a brain-penetrating nanobody in mice
- Open Access
- 5 July 2019
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 7 (1) , 1-19
Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model
Dysregulation of epigenetic mechanisms is emerging as a central event in neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS). In many models of neurodegeneration, global histone acetylation is decreased in the affected neuronal tissues. Histone acetylation is controlled by the antagonistic actions of two protein families –the histone acetyltransferases (HATs) and the histone deacetylases (HDACs). Drugs inhibiting HDAC activity are already used in the clinic as anti-cancer agents. The aim of this study was to explore the therapeutic potential of HDAC inhibition in the context of ALS. We discovered that transgenic mice overexpressing wild-type FUS (“Tg FUS+/+”), which recapitulate many aspects of human ALS, showed reduced global histone acetylation and alterations in metabolic gene expression, resulting in a dysregulated metabolic homeostasis. Chronic treatment of Tg FUS+/+ mice with ACY-738, a potent HDAC inhibitor that can cross the blood-brain barrier, ameliorated the motor phenotype and substantially extended the life span of the Tg FUS+/+ mice. At the molecular level, ACY-738 restored global histone acetylation and metabolic gene expression, thereby re-establishing metabolite levels in the spinal cord. Taken together, our findings link epigenetic alterations to metabolic dysregulation in ALS pathology, and highlight ACY-738 as a potential therapeutic strategy to treat this devastating disease.
- 5 July 2019
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 7 (1) , 1-19
Open AccessRestoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model
Dysregulation of epigenetic mechanisms is emerging as a central event in neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS). In many models of neurodegeneration, global histone acetylation is decreased in the affected neuronal tissues. Histone acetylation is controlled by the antagonistic actions of two protein families –the histone acetyltransferases (HATs) and the histone deacetylases (HDACs). Drugs inhibiting HDAC activity are already used in the clinic as anti-cancer agents. The aim of this study was to explore the therapeutic potential of HDAC inhibition in the context of ALS. We discovered that transgenic mice overexpressing wild-type FUS (“Tg FUS+/+”), which recapitulate many aspects of human ALS, showed reduced global histone acetylation and alterations in metabolic gene expression, resulting in a dysregulated metabolic homeostasis. Chronic treatment of Tg FUS+/+ mice with ACY-738, a potent HDAC inhibitor that can cross the blood-brain barrier, ameliorated the motor phenotype and substantially extended the life span of the Tg FUS+/+ mice. At the molecular level, ACY-738 restored global histone acetylation and metabolic gene expression, thereby re-establishing metabolite levels in the spinal cord. Taken together, our findings link epigenetic alterations to metabolic dysregulation in ALS pathology, and highlight ACY-738 as a potential therapeutic strategy to treat this devastating disease.